{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:28:32Z","timestamp":1787858912697,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1136\/ard-2023-224356","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T13:20:23Z","timestamp":1699276823000},"page":"177-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies"],"prefix":"10.1016","volume":"83","author":[{"given":"Teresa A","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-5296","authenticated-orcid":false,"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleb","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-0616","authenticated-orcid":false,"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-9626","authenticated-orcid":false,"given":"Thomas","family":"Frisell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0147-4112","authenticated-orcid":false,"given":"Yvette","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Khaychuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Dominique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4391-2324","authenticated-orcid":false,"given":"Michael A","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224356_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-2077.94323","article-title":"Nonmelanoma skin cancer","volume":"5","author":"Samarasinghe","year":"2012","journal-title":"J Cutan Aesthet Surg"},{"key":"10.1136\/ard-2023-224356_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.rdc.2004.01.007","article-title":"Associations between rheumatoid arthritis and malignancy","volume":"30","author":"Chakravarty","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2023-224356_bib3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224356_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224356_bib6","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224356_bib7","doi-asserted-by":"crossref","first-page":"22279","DOI":"10.3390\/ijms151222279","article-title":"Smoking and rheumatoid arthritis","volume":"15","author":"Chang","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2023-224356_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1054\/bjoc.2001.1931","article-title":"Non-melanoma skin cancers and glucocorticoid therapy","volume":"85","author":"Karagas","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1136\/ard-2023-224356_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6604796","article-title":"Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study","volume":"100","author":"Jensen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1136\/ard-2023-224356_bib10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/kew214","article-title":"Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study","volume":"55","author":"Lange","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224356_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidem Drug Safe"},{"key":"10.1136\/ard-2023-224356_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1136\/ard-2023-224356_bib13","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"10.1136\/ard-2023-224356_bib14","series-title":"ORENCIA\u00ae (Abatacept) [package insert]","author":"Bristol Myers Squibb","year":"2021"},{"key":"10.1136\/ard-2023-224356_bib15","first-page":"1","article-title":"The macrophages in rheumatic diseases","volume":"9","author":"Laria","year":"2016","journal-title":"J Inflamm Res"},{"key":"10.1136\/ard-2023-224356_bib16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2023-224356_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nri.2016.124","article-title":"The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting","volume":"17","author":"Malmstr\u00f6m","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2023-224356_bib18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224356_bib19","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224356_bib20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224356_bib21","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224356_bib22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or Infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib23","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"Schiff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3B, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular\u2010course juvenile idiopathic arthritis: results from a phase III open\u2010label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224356_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224356_bib29","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224356_bib31","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/ard.2010.139345","article-title":"Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial","volume":"70","author":"Kremer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib32","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","article-title":"Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment","volume":"68","author":"Simon","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224356_bib33","article-title":"Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","author":"Simon","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224356_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/acr2.1034","article-title":"Safety of abatacept versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials","volume":"1","author":"Simon","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2023-224356_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224356_bib36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224356_bib37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12935-021-02325-9","article-title":"Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1136\/ard-2023-224356_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224356_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1136\/ard-2023-224356_bib40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400342X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400342X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:02:23Z","timestamp":1786201343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672400342X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S000349672400342X"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224356","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}